Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news